5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies

[1]  L. Pantanowitz,et al.  Evidence‐based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology , 2021, Cancer cytopathology.

[2]  A. Harbhajanka,et al.  Immunochemistry in the work‐up of mesothelioma and its differential diagnosis and mimickers , 2021, Diagnostic cytopathology.

[3]  A. Churg,et al.  The Separation of Benign and Malignant Mesothelial Proliferations , 2020, The American journal of surgical pathology.

[4]  Jefree J. Schulte,et al.  Application of immunohistochemistry in diagnosis and management of malignant mesothelioma , 2020, Translational lung cancer research.

[5]  S. Dacic,et al.  Usefulness of methylthioadenosine phosphorylase and BRCA‐associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens , 2019, Cancer cytopathology.

[6]  M. Brevet,et al.  The value of BRCA‐1‐associated protein 1 expression and cyclin‐dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens , 2019, Cytopathology : official journal of the British Society for Clinical Cytology.

[7]  S. Jang,et al.  Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists , 2019, Journal of pathology and translational medicine.

[8]  N. Le Stang,et al.  MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma , 2019, Modern Pathology.

[9]  A. Husain,et al.  Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations , 2018, Modern Pathology.

[10]  G. Alí,et al.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. , 2018, Journal of thoracic disease.

[11]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.

[12]  H. Honda,et al.  Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. , 2017, Lung cancer.

[13]  C. Toon,et al.  Loss of expression of BAP1 is very rare in non-small cell lung carcinoma. , 2016, Pathology.

[14]  K. Helin,et al.  Role of TET enzymes in DNA methylation, development, and cancer , 2016, Genes & development.

[15]  A. Gown,et al.  BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations , 2015, The American journal of surgical pathology.

[16]  M. Becich,et al.  High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  R. Attanoos,et al.  The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2 , 2003, Histopathology.